Recombinant Rat LAG3 /CD223 Protein, 100µg

Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Source
Recombinant Rat LAG3, His Tag (LA3-R52H5) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Leu 442 (Accession # NP_997678).
Predicted N-terminus: Gly 24

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.6 kDa. The protein migrates as 55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review"
Li, Chen, Si et al
Biomol Biomed (2024)
(2) "PD-1 and LAG-3 positive T cells are related with the prognosis of patients with chronic kidney disease"
Jiang, Wu, Zhang
Exp Cell Res (2024)
(3) "Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series"
Yamamoto, Tolcher, Hafez et al
Onco Targets Ther (2024) 17, 267-280
Showing 1-3 of 1597 papers.